Loading...
Keywords
Last Name
Institution

Christopher R. Nitkin, MD

TitlePhysician
InstitutionChildren's Mercy Kansas City
DepartmentPediatrics
Address2401 Gilham Rd
Kansas City MO 64108
ORCID ORCID Icon0000-0001-5718-4523 Additional info
vCardDownload vCard
    Other Positions
    TitleAssistant Professor of Pediatrics
    InstitutionUniversity of Missouri-Kansas City
    DepartmentPediatrics

    TitleClinical Assistant Professor of Pediatrics
    InstitutionUniversity of Kansas Medical Center
    DepartmentPediatrics


    Collapse Biography 
    Collapse education and training
    Mount Sinai School of MedicineMD2010
    Connecticut Children's Medical CenterResidency2013Pediatrics
    Rainbow Babies & Children's HospitalFellowship2017Neonatal-Perinatal Medicine

    Collapse Overview 

    Collapse Research 
    Collapse research overview
    Dr. Nitkin is an academic neonatologist with research interests on mesenchymal stem cell (MSC) therapy to prevent and treat neonatal lung disease. He is currently site PI for an industry-funded Phase I clinical trial of MSC-derived exosomes to prevent bronchopulmonary dysplasia in extremely preterm infants. He is also involved with work on automating and modernizing the Center for Infant Pulmonary Disorders registry at CMH to facilitate future research projects across the division.

    Collapse Bibliography 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Nitkin CR, Xia S, Menden H, Yu W, Xiong M, Heruth DP, Ye SQ, Sampath V. FOSL1 is a novel mediator of endotoxin/lipopolysaccharide-induced pulmonary angiogenic signaling. Sci Rep. 2020 Aug 04; 10(1):13143. PMID: 32753701.
      View in: PubMed
    2. Nitkin CR, Rajasingh J, Pisano C, Besner GE, Thébaud B, Sampath V. Stem cell therapy for preventing neonatal diseases in the 21st century: Current understanding and challenges. Pediatr Res. 2020 01; 87(2):265-276. PMID: 31086355.
      View in: PubMed
    3. Auster L, Sutton M, Gwin MC, Nitkin C, Bonfield TL. Optimization of In Vitro Mycobacterium avium and Mycobacteriumintracellulare Growth Assays for Therapeutic Development. Microorganisms. 2019 Feb 01; 7(2). PMID: 30717247.
      View in: PubMed
    4. Nitkin CR, Bonfield TL. Balancing anti-inflammatory and anti-oxidant responses in murine bone marrow derived macrophages. PLoS One. 2017; 12(9):e0184469. PMID: 28886148.
      View in: PubMed
    5. Nitkin CR, Bonfield TL. Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements. Stem Cells Transl Med. 2017 02; 6(2):539-565. PMID: 28191766.
      View in: PubMed
    6. Petty WJ, Li N, Biddle A, Bounds R, Nitkin C, Ma Y, Dragnev KH, Freemantle SJ, Dmitrovsky E. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J Natl Cancer Inst. 2005 Nov 16; 97(22):1645-51. PMID: 16288117.
      View in: PubMed
    Nitkin's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description